CD8A and neoplasm: Targeting the CXCL12-CXCR4 axis by treatment with a specific CXCR4 inhibitor AMD3100 (Figure 1), also known as Plerixafor, reverses FAP-positive CAF-mediated immunosuppression, infiltration of CD8+ T cells into the tumor.